CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective hard but unsuccessfully to develop an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn post, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire interview that I came away with a bad impression of the company.

Irony of irony, my poor opinion of the company has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the technology as well as associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) along with the very first new drug program approval ($five million), and even royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and numerous indications, it’s this individual remedy in addition to a “broad pipeline of indications” as it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an active organization with diverse interests albeit centered on leronlimab, several illness types, multiple presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very start of the interest of mine in this particular organization. Judging by way of the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or maybe some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Published
Categorized as Health

Leave a comment

Your email address will not be published. Required fields are marked *